Table 2.

Association analysis between bad outcome and drug exposure (adjusted by PS)^*,⁎⁎

	Mortality at day 15			Mortality at day 30			Overall mortality
Drug family	OR	95% CI	p	OR	95%CI	p	OR	95%CI	p
ACE2 inhibitor	0.78	(0.5-1.2)	0.2	0.73	(0.5-1.0)	0.07	0.74	(0.5-1.0)	0.08
Inhaled corticoids	0.61	(0.3-1.1)	0.1	0.52	(0.3-0.9)	0.03	0.58	(0.3-1.00)	0.05
Statins	0.77	(0.5-1.2)	0.2	0.65	(0.4-0.9)	0.03	0.69	(0.5-1.0)	0.06
Vitamin D derivatives	0.87	(0.6-1.3)	0.5	0.8	(0.6-1.2)	0.2	0.79	(0.6-1.1)	0.2
Platelet antiaggregants	1.14	(0.8-1.6)	0.4	1.09	(0.8-1.5)	0.6	1.09	(0.8-1.5)	0.6
Anticoagulants	0.91	(0.6-1.4)	0.7	0.78	(0.5-1.2)	0.5	0.76	(0.5-1.1)	0.2
Oral corticoids	1.27	(0.7-2.2)	0.4	1.57	(0.9-2.6)	0.08	1.68	(1.0-2.8)	0.04
ARA-II blockers	1.23	(0.7-1.7)	0.6	1.09	(0.7-1.6)	0.7	1.01	(0.7-1.5)	0.9

^⁎PS included age, gender, respiratory, cardiovascular or cerebrovascular comorbidities, hypertension, dementia, diabetes mellitus type II, Barthel score, frailty score, size of the LTC facility in number of residents.

^⁎⁎Adjustments included drugs under study